Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 326

1.

Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial.

Gennari A, Foca F, Zamarchi R, Rocca A, Amadori D, De Censi A, Bologna A, Cavanna L, Gianni L, Scaltriti L, Rossi E, Facchinetti A, Martini V, Bruzzi P, Nanni O.

Breast Cancer Res Treat. 2020 Mar 21. doi: 10.1007/s10549-020-05596-4. [Epub ahead of print]

PMID:
32200486
3.

Comparison between 18F-FDG-PET- and CT-based criteria in non-small cell lung cancer (NSCLC) patients treated with Nivolumab.

Rossi G, Bauckneht M, Genova C, Rijavec E, Biello F, Mennella S, Dal Bello MG, Cittadini G, Bruzzi P, Piva R, Ceriani V, Sambuceti G, Lopci E, Morbelli S, Grossi F.

J Nucl Med. 2019 Dec 5. pii: jnumed.119.233056. doi: 10.2967/jnumed.119.233056. [Epub ahead of print]

PMID:
31806768
4.

Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab.

Genova C, Boccardo S, Mora M, Rijavec E, Biello F, Rossi G, Tagliamento M, Dal Bello MG, Coco S, Alama A, Vanni I, Barletta G, Bianchi R, Maggioni C, Bruzzi P, Grossi F.

J Clin Med. 2019 Oct 1;8(10). pii: E1566. doi: 10.3390/jcm8101566.

5.

Difficulties in conducting pure academic research, obstacles in data collection and quality of informations: The example of the INTERCEPTOR study.

Merlano M, Denaro N, Benasso M, Licitra L, Bossi P, Locati L, Vecchio S, Bruzzi P.

Oral Oncol. 2019 Oct;97:99-104. doi: 10.1016/j.oraloncology.2019.08.019. Epub 2019 Aug 28.

PMID:
31472438
6.

Sentinel lymph node biopsy in patients with malignant melanoma: analysis of post-operative complications.

Solari N, Bertoglio S, Boscaneanu A, Minuto M, Reina S, Palombo D, Bruzzi P, Cafiero F.

ANZ J Surg. 2019 Sep;89(9):1041-1044. doi: 10.1111/ans.15358. Epub 2019 Jul 31.

PMID:
31368164
7.

Isolated hypoaldosteronism as first sign of X-linked adrenal hypoplasia congenita caused by a novel mutation in NR0B1/DAX-1 gene: a case report.

Iughetti L, Lucaccioni L, Bruzzi P, Ciancia S, Bigi E, Madeo SF, Predieri B, Roucher-Boulez F.

BMC Med Genet. 2019 Jun 4;20(1):98. doi: 10.1186/s12881-019-0834-7.

8.

The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018.

Ascierto PA, Bruzzi P, Eggermont A, Hamid O, Tawbi HA, van Akkooi A, Testori A, Caracò C, Puzanov I, Perrone F.

J Transl Med. 2019 May 10;17(1):148. doi: 10.1186/s12967-019-1892-5.

9.

Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040).

Pai SI, Faivre S, Licitra L, Machiels JP, Vermorken JB, Bruzzi P, Gruenwald V, Giglio RE, Leemans CR, Seiwert TY, Soulieres D.

J Immunother Cancer. 2019 Apr 3;7(1):96. doi: 10.1186/s40425-019-0578-0.

10.

Role of Preoperative Cardiovascular Magnetic Resonance in Planning Ventricular Septal Myectomy in Patients With Obstructive Hypertrophic Cardiomyopathy.

Spirito P, Binaco I, Poggio D, Zyrianov A, Grillo M, Pezzoli L, Rossi J, Malanin D, Vaccari G, Dorobantu L, Iascone M, Mortara A, Khouri T, Bruzzi P, Ferrazzi P.

Am J Cardiol. 2019 May 1;123(9):1517-1526. doi: 10.1016/j.amjcard.2019.01.041. Epub 2019 Feb 8.

PMID:
30791998
11.

Endocrine and metabolic complications in children and adolescents with Sickle Cell Disease: an Italian cohort study.

Mandese V, Bigi E, Bruzzi P, Palazzi G, Predieri B, Lucaccioni L, Cellini M, Iughetti L.

BMC Pediatr. 2019 Feb 11;19(1):56. doi: 10.1186/s12887-019-1423-9.

12.

Long-term effects on growth, development, and metabolism of ALL treatment in childhood.

Bruzzi P, Bigi E, Predieri B, Bonvicini F, Cenciarelli V, Felici F, Iughetti L.

Expert Rev Endocrinol Metab. 2019 Jan;14(1):49-61. doi: 10.1080/17446651.2019.1561271. Epub 2018 Dec 31. Review.

PMID:
30596296
13.

Mortality among workers exposed to asbestos at the shipyard of Genoa, Italy: a 55 years follow-up.

Merlo DF, Bruzzone M, Bruzzi P, Garrone E, Puntoni R, Maiorana L, Ceppi M.

Environ Health. 2018 Dec 29;17(1):94. doi: 10.1186/s12940-018-0439-1.

14.

Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial.

Nanni O, Amadori D, De Censi A, Rocca A, Freschi A, Bologna A, Gianni L, Rosetti F, Amaducci L, Cavanna L, Foca F, Sarti S, Serra P, Valmorri L, Bruzzi P, Corradengo D, Gennari A; MYME investigators.

Breast Cancer Res Treat. 2019 Apr;174(2):433-442. doi: 10.1007/s10549-018-05070-2. Epub 2018 Dec 7.

PMID:
30536182
15.

"Normal values" for the lymphocyte cytokinesis-block micronucleus cytome parameters: Repeatability and reproducibility in a healthy reference population.

Bolognesi C, Bonelli L, Compalati A, Ferla V, Stagnaro L, Ubezio G, Bruzzi P.

Sci Total Environ. 2019 Feb 20;652:513-522. doi: 10.1016/j.scitotenv.2018.10.187. Epub 2018 Oct 15.

PMID:
30368181
16.

Switching From Glargine to Degludec: The Effect on Metabolic Control and Safety During 1-Year of Real Clinical Practice in Children and Adolescents With Type 1 Diabetes.

Predieri B, Suprani T, Maltoni G, Graziani V, Bruzzi P, Zucchini S, Iughetti L.

Front Endocrinol (Lausanne). 2018 Aug 23;9:462. doi: 10.3389/fendo.2018.00462. eCollection 2018.

17.

[Adaptive studies to assess drug effectiveness].

Bruzzi P, Traversa G.

Epidemiol Prev. 2018 May-Aug;42(3-4):251-253. doi: 10.19191/EP18.3-4.P251.073. Italian.

PMID:
30066527
18.

Adjusting insulin doses in patients with type 1 diabetes who use insulin pump and continuous glucose monitoring: Variations among countries and physicians.

Nimri R, Dassau E, Segall T, Muller I, Bratina N, Kordonouri O, Bello R, Biester T, Dovc K, Tenenbaum A, Brener A, Šimunović M, Sakka SD, Nevo Shenker M, Passone CG, Rutigliano I, Tinti D, Bonura C, Caiulo S, Ruszala A, Piccini B, Giri D, Stein R, Rabbone I, Bruzzi P, Omladič JŠ, Steele C, Beccuti G, Yackobovitch-Gavan M, Battelino T, Danne T, Atlas E, Phillip M.

Diabetes Obes Metab. 2018 Oct;20(10):2458-2466. doi: 10.1111/dom.13408. Epub 2018 Jul 18.

19.

Leucocytes telomere length and breast cancer risk/ susceptibility: A case-control study.

Pavanello S, Varesco L, Gismondi V, Bruzzi P, Bolognesi C.

PLoS One. 2018 May 21;13(5):e0197522. doi: 10.1371/journal.pone.0197522. eCollection 2018.

20.

Different View on Larynx Preservation Evidence-Based Treatment Recommendations.

Licitra L, Bonomo P, Sanguineti G, Bacigalupo A, Baldi GG, Valerini S, Bruzzi P.

J Clin Oncol. 2018 May 1;36(13):1376-1377. doi: 10.1200/JCO.2018.77.8001. Epub 2018 Mar 20. No abstract available.

PMID:
29558275
21.

Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines.

Mikulska M, Averbuch D, Tissot F, Cordonnier C, Akova M, Calandra T, Ceppi M, Bruzzi P, Viscoli C; European Conference on Infections in Leukemia (ECIL).

J Infect. 2018 Jan;76(1):20-37. doi: 10.1016/j.jinf.2017.10.009. Epub 2017 Oct 25.

PMID:
29079323
22.

Functional Activation of Osteoclast Commitment in Chronic Lymphocytic Leukaemia: a Possible Role for RANK/RANKL Pathway.

Marini C, Bruno S, Fiz F, Campi C, Piva R, Cutrona G, Matis S, Nieri A, Miglino M, Ibatici A, Maria Orengo A, Maria Massone A, Neumaier CE, Totero D, Giannoni P, Bauckneht M, Pennone M, Tenca C, Gugiatti E, Bellini A, Borra A, Tedone E, Efetürk H, Rosa F, Emionite L, Cilli M, Bagnara D, Brucato V, Bruzzi P, Piana M, Fais F, Sambuceti G.

Sci Rep. 2017 Oct 26;7(1):14159. doi: 10.1038/s41598-017-12761-1.

23.

A Score-Based Approach to 18F-FDG PET Images as a Tool to Describe Metabolic Predictors of Myocardial Doxorubicin Susceptibility.

Bauckneht M, Morbelli S, Fiz F, Ferrarazzo G, Piva R, Nieri A, Sarocchi M, Spallarossa P, Canepari ME, Arboscello E, Bellodi A, Massaia M, Gallamini A, Bruzzi P, Marini C, Sambuceti G.

Diagnostics (Basel). 2017 Oct 26;7(4). pii: E57. doi: 10.3390/diagnostics7040057.

24.

Prognostic factors in chronic subdural hematoma: results from a monocentric consecutive surgical series of 605 patients.

Bacigaluppi S, Guastalli F, Bragazzi NL, Balestrino A, Bruzzi P, Zona G.

J Neurosurg Sci. 2017 Sep 28. doi: 10.23736/S0390-5616.17.04103-0. [Epub ahead of print]

PMID:
28959873
25.

Central Precocious Puberty and Response to GnRHa Therapy in Children with Cerebral Palsy and Moderate to Severe Motor Impairment: Data from a Longitudinal, Case-Control, Multicentre, Italian Study.

Bruzzi P, Messina MF, Bartoli A, Predieri B, Lucaccioni L, Madeo SF, Verrotti A, De Luca F, Iughetti L.

Int J Endocrinol. 2017;2017:4807163. doi: 10.1155/2017/4807163. Epub 2017 Jul 16.

26.

The urgent need to improve the tools to assess clinical benefit and value of cancer treatment.

Sobrero A, Puccini A, Bregni G, Bruzzi P.

Eur J Cancer. 2017 Sep;83:324-328. doi: 10.1016/j.ejca.2017.04.029. Epub 2017 Jul 24.

PMID:
28751070
27.

Doxorubicin Effect on Myocardial Metabolism as a Prerequisite for Subsequent Development of Cardiac Toxicity: A Translational 18F-FDG PET/CT Observation.

Bauckneht M, Ferrarazzo G, Fiz F, Morbelli S, Sarocchi M, Pastorino F, Ghidella A, Pomposelli E, Miglino M, Ameri P, Emionite L, Ticconi F, Arboscello E, Buschiazzo A, Massimelli EA, Fiordoro S, Borra A, Cossu V, Bozzano A, Ibatici A, Ponzoni M, Spallarossa P, Gallamini A, Bruzzi P, Sambuceti G, Marini C.

J Nucl Med. 2017 Oct;58(10):1638-1645. doi: 10.2967/jnumed.117.191122. Epub 2017 Jun 23.

28.

Ricerca clinica, tra presunti sprechi e governance dell’innovazione.

Perrone F, Addis A, Sinagra G, Bruzzi P.

Recenti Prog Med. 2017 May;108(5):207-210. doi: 10.1701/2695.27556. Italian. No abstract available.

PMID:
28643810
29.

Timely diagnosis of sitosterolemia by next generation sequencing in two children with severe hypercholesterolemia.

Buonuomo PS, Iughetti L, Pisciotta L, Rabacchi C, Papadia F, Bruzzi P, Tummolo A, Bartuli A, Cortese C, Bertolini S, Calandra S.

Atherosclerosis. 2017 Jul;262:71-77. doi: 10.1016/j.atherosclerosis.2017.05.002. Epub 2017 May 4.

PMID:
28521186
30.

Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.

Gronchi A, Ferrari S, Quagliuolo V, Broto JM, Pousa AL, Grignani G, Basso U, Blay JY, Tendero O, Beveridge RD, Ferraresi V, Lugowska I, Merlo DF, Fontana V, Marchesi E, Donati DM, Palassini E, Palmerini E, De Sanctis R, Morosi C, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Casali PG.

Lancet Oncol. 2017 Jun;18(6):812-822. doi: 10.1016/S1470-2045(17)30334-0. Epub 2017 May 9. Erratum in: Lancet Oncol. 2017 Jun;18(6):e301.

PMID:
28499583
31.

Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis.

Poggio F, Ceppi M, Lambertini M, Bruzzi P, Ugolini D, Bighin C, Levaggi A, Giraudi S, D'Alonzo A, Vaglica M, Blondeaux E, Sertoli MR, Pronzato P, Del Mastro L.

Breast. 2017 Jun;33:104-108. doi: 10.1016/j.breast.2017.03.011. Epub 2017 Mar 27. Review.

PMID:
28360014
32.

Methodological issues in the choice among different drugs approved for the same therapeutic indication: a position paper by the Italian Association of Medical Oncology (AIOM).

Di Maio M, Bruzzi P, Perrone F, Torri V, Montemurro F, Tiseo M, Vasile E.

ESMO Open. 2016 Dec 12;1(6):e000109. doi: 10.1136/esmoopen-2016-000109. eCollection 2016. Review.

33.

Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group.

Stacchiotti S, Gronchi A, Fossati P, Akiyama T, Alapetite C, Baumann M, Blay JY, Bolle S, Boriani S, Bruzzi P, Capanna R, Caraceni A, Casadei R, Colia V, Debus J, Delaney T, Desai A, Dileo P, Dijkstra S, Doglietto F, Flanagan A, Froelich S, Gardner PA, Gelderblom H, Gokaslan ZL, Haas R, Heery C, Hindi N, Hohenberger P, Hornicek F, Imai R, Jeys L, Jones RL, Kasper B, Kawai A, Krengli M, Leithner A, Logowska I, Martin Broto J, Mazzatenta D, Morosi C, Nicolai P, Norum OJ, Patel S, Penel N, Picci P, Pilotti S, Radaelli S, Ricchini F, Rutkowski P, Scheipl S, Sen C, Tamborini E, Thornton KA, Timmermann B, Torri V, Tunn PU, Uhl M, Yamada Y, Weber DC, Vanel D, Varga PP, Vleggeert-Lankamp CLA, Casali PG, Sommer J.

Ann Oncol. 2017 Jun 1;28(6):1230-1242. doi: 10.1093/annonc/mdx054. Review.

34.

Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study.

Bighin C, Dozin B, Poggio F, Ceppi M, Bruzzi P, D'Alonzo A, Levaggi A, Giraudi S, Lambertini M, Miglietta L, Vaglica M, Fontana V, Iacono G, Pronzato P, Del Mastro L.

Oncotarget. 2017 Jul 4;8(27):44800-44810. doi: 10.18632/oncotarget.14735.

35.

Prediction of Diabetes Remission at Long Term Following Biliopancreatic Diversion.

Scopinaro N, Adami GF, Bruzzi P, Cordera R.

Obes Surg. 2017 Jul;27(7):1705-1708. doi: 10.1007/s11695-017-2555-3.

PMID:
28101844
36.

Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies.

Lambertini M, Ceppi M, Cognetti F, Cavazzini G, De Laurentiis M, De Placido S, Michelotti A, Bisagni G, Durando A, Valle E, Scotto T, De Censi A, Turletti A, Benasso M, Barni S, Montemurro F, Puglisi F, Levaggi A, Giraudi S, Bighin C, Bruzzi P, Del Mastro L; MIG and GIM study groups.

Eur J Cancer. 2017 Jan;71:34-42. doi: 10.1016/j.ejca.2016.10.030. Epub 2016 Dec 10.

PMID:
27951450
37.

Previous bloodstream infections due to other pathogens as predictors of carbapenem-resistant Klebsiella pneumoniae bacteraemia in colonized patients: results from a retrospective multicentre study.

Giacobbe DR, Del Bono V, Bruzzi P, Corcione S, Giannella M, Marchese A, Magnasco L, Maraolo AE, Pagani N, Saffioti C, Ambretti S, Cardellino CS, Coppo E, De Rosa FG, Viale P, Viscoli C; ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva).

Eur J Clin Microbiol Infect Dis. 2017 Apr;36(4):663-669. doi: 10.1007/s10096-016-2843-1. Epub 2016 Dec 1.

PMID:
27909821
38.

Treatment with aromatase inhibitors and markers of cardiovascular disease.

Blondeaux E, Musio D, Bruzzi P, Lambertini M, Gazzola V, Poggio F, Vecchio S, Levaggi A, D'Alonzo A, Perfumo MC, Bighin C, Giraudi S, Palombo D, Del Mastro L.

Breast Cancer Res Treat. 2016 Nov;160(2):261-267. Epub 2016 Sep 23.

PMID:
27663435
39.

Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy.

Gennari A, Amadori D, Scarpi E, Farolfi A, Paradiso A, Mangia A, Biglia N, Gianni L, Tienghi A, Rocca A, Maltoni R, Antonucci G, Bruzzi P, Nanni O.

Breast Cancer Res Treat. 2016 Aug;159(1):79-86. doi: 10.1007/s10549-016-3923-8. Epub 2016 Jul 26.

PMID:
27460638
40.

A PET/CT approach to spinal cord metabolism in amyotrophic lateral sclerosis.

Marini C, Cistaro A, Campi C, Calvo A, Caponnetto C, Nobili FM, Fania P, Beltrametti MC, Moglia C, Novi G, Buschiazzo A, Perasso A, Canosa A, Scialò C, Pomposelli E, Massone AM, Bagnara MC, Cammarosano S, Bruzzi P, Morbelli S, Sambuceti G, Mancardi G, Piana M, Chiò A.

Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):2061-71. doi: 10.1007/s00259-016-3440-3. Epub 2016 Jul 15.

41.

SINODAR ONE, an ongoing randomized clinical trial to assess the role of axillary surgery in breast cancer patients with one or two macrometastatic sentinel nodes.

Tinterri C, Canavese G, Bruzzi P, Dozin B.

Breast. 2016 Dec;30:197-200. doi: 10.1016/j.breast.2016.06.016. Epub 2016 Jul 9.

PMID:
27406897
42.

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib.

Queirolo P, Spagnolo F, Picasso V, Spano L, Tanda E, Fontana V, Giorello L, Merlo DF, Simeone E, Grimaldi AM, Curvietto M, Del Vecchio M, Bruzzi P, Ascierto PA.

Oncotarget. 2016 Jul 13;9(15):12408-12417. doi: 10.18632/oncotarget.10589. eCollection 2018 Feb 23.

43.

Estimating a treatment effect: Choosing between relative and absolute measures.

Sormani MP, Bruzzi P.

Mult Scler. 2017 Feb;23(2):197-200. doi: 10.1177/1352458516645671. Epub 2016 Jul 11.

PMID:
27207463
44.

Menstrual patterns, fertility and main pregnancy outcomes after allogeneic haematopoietic stem cell transplantation.

Chiodi S, Spinelli S, Bruzzi P, Anserini P, Di Grazia C, Bacigalupo A.

J Obstet Gynaecol. 2016 Aug;36(6):783-788. Epub 2016 May 6.

PMID:
27153290
45.

Comparison of coronary flow reserve estimated by dynamic radionuclide SPECT and multi-detector x-ray CT.

Marini C, Seitun S, Zawaideh C, Bauckneht M, Morelli MC, Ameri P, Ferrarazzo G, Budaj I, Balbi M, Fiz F, Boccalini S, Pregliasco AG, Buschiazzo A, Saracco A, Bagnara MC, Bruzzi P, Brunelli C, Ferro C, Bezante GP, Sambuceti G.

J Nucl Cardiol. 2017 Oct;24(5):1712-1721. doi: 10.1007/s12350-016-0492-5. Epub 2016 May 5.

PMID:
27151303
46.

Unusual presentation of Rosai-Dorfman disease in a 14-month-old Italian child: a case report and review of the literature.

di Dio F, Mariotti I, Coccolini E, Bruzzi P, Predieri B, Iughetti L.

BMC Pediatr. 2016 May 3;16:62. doi: 10.1186/s12887-016-0595-9. Review.

47.

Genetic and epigenetic factors affect RET gene expression in breast cancer cell lines and influence survival in patients.

Griseri P, Garrone O, Lo Sardo A, Monteverde M, Rusmini M, Tonissi F, Merlano M, Bruzzi P, Lo Nigro C, Ceccherini I.

Oncotarget. 2016 May 3;7(18):26465-79. doi: 10.18632/oncotarget.8417.

48.

Peripherally inserted central catheters (PICCs) in cancer patients under chemotherapy: A prospective study on the incidence of complications and overall failures.

Bertoglio S, Faccini B, Lalli L, Cafiero F, Bruzzi P.

J Surg Oncol. 2016 May;113(6):708-14. doi: 10.1002/jso.24220. Epub 2016 Mar 29.

PMID:
27020965
49.

Sentinel Lymph Node Biopsy Versus Axillary Dissection in Node-Negative Early-Stage Breast Cancer: 15-Year Follow-Up Update of a Randomized Clinical Trial.

Canavese G, Bruzzi P, Catturich A, Tomei D, Carli F, Garrone E, Spinaci S, Lacopo F, Tinterri C, Dozin B.

Ann Surg Oncol. 2016 Aug;23(8):2494-500. doi: 10.1245/s10434-016-5177-4. Epub 2016 Mar 14.

PMID:
26975739
50.

Differences in the carcinogenic evaluation of glyphosate between the International Agency for Research on Cancer (IARC) and the European Food Safety Authority (EFSA).

Portier CJ, Armstrong BK, Baguley BC, Baur X, Belyaev I, Bellé R, Belpoggi F, Biggeri A, Bosland MC, Bruzzi P, Budnik LT, Bugge MD, Burns K, Calaf GM, Carpenter DO, Carpenter HM, López-Carrillo L, Clapp R, Cocco P, Consonni D, Comba P, Craft E, Dalvie MA, Davis D, Demers PA, De Roos AJ, DeWitt J, Forastiere F, Freedman JH, Fritschi L, Gaus C, Gohlke JM, Goldberg M, Greiser E, Hansen J, Hardell L, Hauptmann M, Huang W, Huff J, James MO, Jameson CW, Kortenkamp A, Kopp-Schneider A, Kromhout H, Larramendy ML, Landrigan PJ, Lash LH, Leszczynski D, Lynch CF, Magnani C, Mandrioli D, Martin FL, Merler E, Michelozzi P, Miligi L, Miller AB, Mirabelli D, Mirer FE, Naidoo S, Perry MJ, Petronio MG, Pirastu R, Portier RJ, Ramos KS, Robertson LW, Rodriguez T, Röösli M, Ross MK, Roy D, Rusyn I, Saldiva P, Sass J, Savolainen K, Scheepers PT, Sergi C, Silbergeld EK, Smith MT, Stewart BW, Sutton P, Tateo F, Terracini B, Thielmann HW, Thomas DB, Vainio H, Vena JE, Vineis P, Weiderpass E, Weisenburger DD, Woodruff TJ, Yorifuji T, Yu IJ, Zambon P, Zeeb H, Zhou SF.

J Epidemiol Community Health. 2016 Aug;70(8):741-5. doi: 10.1136/jech-2015-207005. Epub 2016 Mar 3. No abstract available.

Supplemental Content

Loading ...
Support Center